Scientific Advisory Board | Dendrite Clinical Systems

Two distinguished members join Dendrite’s Scientific Advisory Board

Dendrite Clinical Systems has announced the appointment of two members to the company’s newly established Scientific Advisory Board - Sir Bruce Keogh (KBE FMedSci FRCS FRCP) and Professor Anthony Goldstone (CBE MA (Oxon) FRCP FRCPE FRCPath). The Scientific Advisory Board has been created to provide unique advice and guidance to Dendrite’s management team by taking an objective look at our activities and sharing with us their experience and knowledge. This includes evaluating the scientific merit of projects, assessing progress and offering strategic input on the company’s priorities.

13 September 2024

UzAMBS and Dendrite Clinical Systems to establish National Registry of Bariatric and Metabolic Surgery of Uzbekistan

The Association of Bariatric and Metabolic Surgeons of Uzbekistan (UzAMBS) and Dendrite Clinical Systems will establish a National Registry of Bariatric and Metabolic Surgery of Uzbekistan.

6 July 2024

Dendrite and LumiThera initiate EUROLIGHT Registry Study to Evaluate Long-term Benefits of Photobiomodulation (PBM) Treatment using the Valeda® Light Delivery System in Patients with Dry Age-Related Macular Degeneration

Dendrite Clinical Systems and LumiThera have initiated the largest photobiomodulation (PBM) study ever conducted. The multi-center clinical registry, EUROLIGHT (European Union Registry Study) will enroll 500 to 1000 patients treated with with PBM using the LumiThera Valeda Light Delivery System in the EU over the past three years. The study will initially include up to 20 European centres and could be expanded in other countries outside the Europe Union (EU) where Valeda is approved.

4 January 2024

SBMSK and Dendrite Clinical Systems to establish National Registry of Bariatric and Metabolic Surgery of Kazakhstan

The Society of Bariatric and Metabolic Surgeons of Kazakhstan (SBMSK) and Dendrite Clinical Systems will establish a National Registry of Bariatric and Metabolic Surgery of Kazakhstan. The purpose of the Registry is to collect information on patients and bariatric procedures in the country so researchers can use the data to improve outcomes in patients.

25 November 2023

State of Kuwait Ministry of Health publishes 3rd National Bariatric Registry Report

The State of Kuwait Ministry of Health and Dendrite are delighted to announce the publication of the 3rd Kuwait National Bariatric Registry Report 2023. This latest report, which includes 6,484 bariatric surgery cases, contains data on baseline obesity-related disease, operation types, operative outcomes and disease status after bariatric surgery in Kuwait.

23 October 2023

Leading UK clinic to launch Dendrite's comprehensive obesity workflow system

The multi-disciplinary team (MDT) at Luton and Dunstable Hospital's Obesity Clinic, working in conjunction with Dendrite Clinical Systems, have developed a single database that tracks at every stage the patient’s entire treatment pathway. The new system records and collects data from the initial patient referral and pre-clinical assessments to each element of their MDT experience, obesity treatment/s, as well as follow-up appointments.

6 June 2023

Scientific Advisory Board

Dendrite's Scientific Advisory Board

Professor Sir Bruce Keogh

Sir Bruce Keogh KBE FMedSci FRCS FRCP has had a distinguished international career as a cardiac surgeon. He developed a longstanding interest in clinical outcomes from working closely with Dendrite to establish a national database for adult cardiac surgery early in his surgical career.

He subsequently became chair of Cardiac Surgery at University College London and Director of Surgery at the Heart Hospital, before being appointed Medical Director of the National Health Service and Director General in the Department of Health, a role that later transferred to NHS England. During this period (2007-18) as the most senior doctor in the NHS he was had particular responsibility for the development and implementation clinical policy and strategy across the health service in England. In the Department of Health, he was the Government sponsor for NICE, the Healthcare Commission and the National Patient Safety Agency. He has served on several boards including NHS England.

He is currently Chair of the Birmingham Women’s and Children’s NHS Foundation Trust. He has been ranked as the most influential clinician in the NHS by the HSJ and named as one of Britain’s 500 most influential people in the Sunday Times. He was knighted for Services to Medicine in 2003.

Professor Anthony Goldstone

Professor Anthony Goldstone CBE MA(Oxon) FRCP FRCPE FRCPath is a senior haematology specialist with over 35 years’ experience of working in the NHS. He was appointed as a Consultant at University College Hospital (UCH) in 1976 and initiated the first stages of what became the biggest Adult Haematology unit in the UK.

Professor Goldstone is a former Medical Director of University College London Hospital, former President of the British Society of Haematology and former Chair of the European Society for Blood and Marrow Transplantation Lymphoma Group. He specialises in adult haematology and haematological malignancy, adult leukaemia, lymphoma (Hodgkin's and Non-Hodgkin's Lymphoma) and myeloma and other non-malignant haematological conditions. The founder of the stem cell transplant unit at UCH, Professor Goldstone is a renowned pioneer in haematological stem cell transplantation.

A Principal Investigator on many leukaemia trials in the UK and internationally, he is strong advocate of evidence-based medicine and believes registries now stand alongside randomised clinical trials as real-world evidence. Professor Goldstone, a former Director of the North London Cancer Network, has published over 360 peer-reviewed papers in haematology and has authored three books. He was awarded a CBE June 2008 for Services to Medicine.